Cargando…

High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection

A 39-year-old woman with systemic lupus erythematosus treated with anti-CD20 monoclonal antibody rituximab was admitted to our hospital with COVID-19 pneumonia. Despite receiving dexamethasone, she developed hypoxaemia and persistent lung opacities. As bronchoalveolar lavage was suggestive of crypto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moutinho-Pereira, Sara, Calisto, Raquel, Sabio, Federico, Guerreiro, Luísa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388267/ https://www.ncbi.nlm.nih.gov/pubmed/34433539 http://dx.doi.org/10.1136/bcr-2021-244853

Ejemplares similares

Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus
por: Mackay, Meggan, et al.
Publicado: (2015)

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
por: Devos, Timothy, et al.
Publicado: (2022)

Protracted course of SARS-CoV-2 pneumonia in moderately to severely immunocompromised patients
por: Lee, Jeongjae, et al.
Publicado: (2023)

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
por: Hueso, Thomas, et al.
Publicado: (2020)

Correction to: Protracted course of SARS‑CoV‑2 pneumonia in moderately to severely immunocompromised patients
por: Lee, Jeongjae, et al.
Publicado: (2023)

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
por: Nguyen, Dung, et al.
Publicado: (2021)

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
por: Rodionov, Roman N, et al.
Publicado: (2021)

Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment
por: Chen, Liang, et al.
Publicado: (2021)

Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery
por: Basheer, Maamoun, et al.
Publicado: (2021)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”
por: Dioverti, Veronica, et al.
Publicado: (2022)

Lupus pneumonitis presenting with high titre of anti‐Ro antibody
por: Chen, Mei‐Chuan, et al.
Publicado: (2017)

T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
por: Bunse, Till, et al.
Publicado: (2023)

Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report
por: Casarola, Genni, et al.
Publicado: (2021)

Neutralizing antibody titres in SARS-CoV-2 infections
por: Lau, Eric H. Y., et al.
Publicado: (2021)

Convalescent plasma therapy in an immunocompromised patient with multiple COVID‐19 flares: a case report
por: Karaolidou, Frini, et al.
Publicado: (2021)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

Case of Acute Disseminated Encephalomyelitis Associated with Cytomegalovirus Reactivation in an Immunocompromised Systemic Lupus Erythematosus Patient
por: Pavicic Ivelja, Mirela, et al.
Publicado: (2021)

Protracted yet coordinated differentiation of long-lived SARS-CoV-2-specific CD8+ T cells during COVID-19 convalescence
por: Ma, Tongcui, et al.
Publicado: (2021)

SARS-CoV-2 and Systemic Lupus Erythematosus
por: Thanou, Aikaterini, et al.
Publicado: (2021)

Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients
por: Beraud, Mickael, et al.
Publicado: (2022)

Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?
por: Hanssen, Jaap L. J., et al.
Publicado: (2021)

Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults
por: Erice, Alejo, et al.
Publicado: (2022)

Physical Fitness and Body Composition in Women with Systemic Lupus Erythematosus
por: Sola-Rodríguez, Sergio, et al.
Publicado: (2019)

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
por: Desmarets, Maxime, et al.
Publicado: (2023)

The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
por: Fisher, David L., et al.
Publicado: (2021)

Convalescent plasma for SARS-CoV-2 infection: win or learn
por: Contreras-Barbeta, Enric, et al.
Publicado: (2022)

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
por: Steenhuis, Maurice, et al.
Publicado: (2021)

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
por: Natarajan, Harini, et al.
Publicado: (2021)

Plasma Cell Differentiation Pathways in Systemic Lupus Erythematosus
por: Malkiel, Susan, et al.
Publicado: (2018)

High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
por: Huygens, Sammy, et al.
Publicado: (2023)

Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus
por: Martin, Myriam, et al.
Publicado: (2017)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Physical Fitness Attenuates the Impact of Higher Body Mass and Adiposity on Inflammation in Women With Systemic Lupus Erythematosus
por: Sola-Rodríguez, Sergio, et al.
Publicado: (2021)

Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis
por: Barreira, Daniela Ferreira, et al.
Publicado: (2021)

SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin
por: Volk, Andreas, et al.
Publicado: (2021)

Sclerostin as a biomarker of cardiovascular risk in women with systemic lupus erythematosus
por: Garcia-de los Ríos, Carlos, et al.
Publicado: (2022)

Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations
por: Jungbauer, Christof, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jdrn7apbmmfuqr0bvo2feeqve4